Compare Stocks: ADVM, EDIT, SVA, and EIKN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
EDIT Editas Medicine	$2.37 -3.0%	$2.84	$1.66 ▼ $4.28	$364.75M	2	2.24 million shs	1.07 million shs
EIKN Eikon Therapeutics	$7.30 -3.2%	$9.44	$6.45 ▼ $17.40	$397.84M	N/A	426,452 shs	331,113 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$368.91M	0.35	N/A	N/A

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	-2.68%
EDIT Editas Medicine	+7.49%	-14.08%	-7.22%	-18.12%	-39.90%
EIKN Eikon Therapeutics	+7.56%	+0.53%	-20.55%	-22.82%	+753,999,900.00%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
EDIT Editas Medicine	$2.37 -3.0%	$2.84	$1.66 ▼ $4.28	$364.75M	2	2.24 million shs	1.07 million shs
EIKN Eikon Therapeutics	$7.30 -3.2%	$9.44	$6.45 ▼ $17.40	$397.84M	N/A	426,452 shs	331,113 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$368.91M	0.35	N/A	N/A

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	-2.68%
EDIT Editas Medicine	+7.49%	-14.08%	-7.22%	-18.12%	-39.90%
EIKN Eikon Therapeutics	+7.56%	+0.53%	-20.55%	-22.82%	+753,999,900.00%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.00	Hold	$4.88	11.81% Upside
EDIT Editas Medicine	2.71	Moderate Buy	$5.83	144.58% Upside
EIKN Eikon Therapeutics	2.56	Moderate Buy	$24.67	233.33% Upside
SVA Sinovac Biotech	3.00	Buy	$1.00	-84.54% Downside

Current Analyst Ratings Breakdown

Latest ADVM, EDIT, SVA, and EIKN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	EIKN Eikon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$23.00
10/8/2026	EDIT Editas Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Equal Weight ➝ Overweight	$4.00 ➝ $6.00
9/23/2026	EDIT Editas Medicine	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$5.00
9/16/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/8/2026	SVA Sinovac Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$6.00 ➝ $1.00
9/7/2026	EIKN Eikon Therapeutics	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/21/2026	EIKN Eikon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$6.00
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E-) ➝ Sell (E)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	$3.40 per share	N/A
EDIT Editas Medicine	$40.52M	9.04	N/A	N/A	$0.28 per share	8.52
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	$402.82M	0.92	$0.54 per share	11.89	$89.01 per share	0.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$8.58	N/A	N/A	N/A	N/A	-3,476.17%	-152.07%	N/A
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ADVM, EDIT, SVA, and EIKN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	EDIT Editas Medicine	-$0.21	N/A	N/A	N/A	$4.54 million	N/A
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	0.65	0.65
EDIT Editas Medicine	N/A	3.19	3.19
EIKN Eikon Therapeutics	N/A	9.89	9.89
SVA Sinovac Biotech	0.04	6.07	5.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
EDIT Editas Medicine	71.90%
EIKN Eikon Therapeutics	N/A
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
EDIT Editas Medicine	3.10%
EIKN Eikon Therapeutics	N/A
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	22.08 million	20.75 million	Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
SVA Sinovac Biotech	3,008	57.02 million	86.89 million	Optionable

ADVM, EDIT, SVA, and EIKN Headlines

Recent News About These Companies

Sernova, Seraxis Aim for Type 1 Diabetes ‘Functional Cure’ With BetaNova Merger

October 4, 2026 | defenseworld.netD

Sinovac Biotech Corporate Event Calendar | NASDAQ:SVA

July 21, 2026 | benzinga.com

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend

July 15, 2026 | businesswire.com

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

July 12, 2026 | businesswire.com

Sinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual Report

June 15, 2026 | tipranks.com

Sinovac Biotech Ltd.

June 8, 2026 | edition.cnn.com

SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F

June 5, 2026 | businesswire.com

Sinovac Faces New Nasdaq Delisting Risk After Regaining Compliance

May 29, 2026 | tipranks.com

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

May 29, 2026 | businesswire.com

SVA Share News Today

May 16, 2026 | uk.investing.com

SINOVAC Reports Unaudited First Half of 2025 Financial Results

May 8, 2026 | businesswire.com

Sinovac Biotech Delays Key Annual 20-F Filing

April 30, 2026 | tipranks.com

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024

April 30, 2026 | businesswire.com

Clearwater Recovery Partners LLP Announces Cash Offer to Purchase Common Shares in Sinovac Biotech Ltd.

March 28, 2026 | tennessean.comT

Sinovac Controlling Shareholders Escape Investor Disclosure Suit

February 25, 2026 | news.bloomberglaw.comN

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

January 22, 2026 | businesswire.com

Sinovac Biotech receives Nasdaq notification regarding late filing of FY25

January 4, 2026 | msn.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | financialpost.comF

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

January 4, 2026 | businesswire.com

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

January 4, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADVM, EDIT, SVA, and EIKN Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Editas Medicine NASDAQ:EDIT

$2.37 -0.07 (-3.03%)

As of 03:38 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Eikon Therapeutics NASDAQ:EIKN

$7.30 -0.24 (-3.18%)

As of 03:38 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 10/15/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADVM, EDIT, SVA, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADVM, EDIT, SVA, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADVM, EDIT, SVA, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADVM, EDIT, SVA, and EIKN Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Editas Medicine NASDAQ:EDIT

Eikon Therapeutics NASDAQ:EIKN

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADVM, EDIT, SVA, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADVM, EDIT, SVA, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADVM, EDIT, SVA, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ADVM, EDIT, SVA, and EIKN Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Editas Medicine NASDAQ:EDIT

Eikon Therapeutics NASDAQ:EIKN

Sinovac Biotech NASDAQ:SVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools